| dc.contributor |
Massachusetts Institute of Technology. Department of Biology |
|
| dc.contributor |
Whitehead Institute for Biomedical Research |
|
| dc.contributor |
Koch Institute for Integrative Cancer Research at MIT |
|
| dc.contributor |
Sabatini, David M. |
|
| dc.creator |
Liu, Qingsong |
|
| dc.creator |
Ren, Tao |
|
| dc.creator |
Fresques, Tara |
|
| dc.creator |
Oppliger, Wolfgang |
|
| dc.creator |
Niles, Brad J. |
|
| dc.creator |
Hur, Wooyoung |
|
| dc.creator |
Hall, Michael N. |
|
| dc.creator |
Powers, Ted |
|
| dc.creator |
Gray, Nathanael S. |
|
| dc.creator |
Sabatini, David |
|
| dc.date |
2015-04-23T14:56:38Z |
|
| dc.date |
2015-04-23T14:56:38Z |
|
| dc.date |
2012-04 |
|
| dc.date |
2012-02 |
|
| dc.identifier |
1554-8929 |
|
| dc.identifier |
1554-8937 |
|
| dc.identifier |
http://hdl.handle.net/1721.1/96732 |
|
| dc.identifier |
Liu, Qingsong, Tao Ren, Tara Fresques, Wolfgang Oppliger, Brad J. Niles, Wooyoung Hur, David M. Sabatini, Michael N. Hall, Ted Powers, and Nathanael S. Gray. “Selective ATP-Competitive Inhibitors of TOR Suppress Rapamycin-Insensitive Function of TORC2 in Saccharomyces Cerevisiae.” ACS Chemical Biology 7, no. 6 (June 15, 2012): 982–987. |
|
| dc.identifier |
https://orcid.org/0000-0002-1446-7256 |
|
| dc.description |
The target of rapamycin (TOR) is a critical regulator of growth, survival, and energy metabolism. The allosteric TORC1 inhibitor rapamycin has been used extensively to elucidate the TOR related signal pathway but is limited by its inability to inhibit TORC2. We used an unbiased cell proliferation assay of a kinase inhibitor library to discover QL-IX-55 as a potent inhibitor of S. cerevisiae growth. The functional target of QL-IX-55 is the ATP-binding site of TOR2 as evidenced by the discovery of resistant alleles of TOR2 through rational design and unbiased selection strategies. QL-IX-55 is capable of potently inhibiting both TOR complex 1 and 2 (TORC1 and TORC2) as demonstrated by biochemical IP kinase assays (IC[subscript 50] <50 nM) and cellular assays for inhibition of substrate YPK1 phosphorylation. In contrast to rapamycin, QL-IX-55 is capable of inhibiting TORC2-dependent transcription, which suggests that this compound will be a powerful probe to dissect the Tor2/TORC2-related signaling pathway in yeast. |
|
| dc.format |
application/pdf |
|
| dc.language |
en_US |
|
| dc.publisher |
American Chemical Society (ACS) |
|
| dc.relation |
http://dx.doi.org/10.1021/cb300058v |
|
| dc.relation |
ACS Chemical Biology |
|
| dc.rights |
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. |
|
| dc.source |
PMC |
|
| dc.title |
Selective ATP-Competitive Inhibitors of TOR Suppress Rapamycin-Insensitive Function of TORC2 in S. cerevisiae |
|
| dc.title |
Selective ATP-Competitive Inhibitors of TOR Suppress Rapamycin-Insensitive Function of TORC2 in Saccharomyces cerevisiae |
|
| dc.type |
Article |
|
| dc.type |
http://purl.org/eprint/type/JournalArticle |
|